Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Alexander C. J. van Akkooi"'
Autor:
Julia Boshuizen, David W. Vredevoogd, Oscar Krijgsman, Maarten A. Ligtenberg, Stephanie Blankenstein, Beaunelle de Bruijn, Dennie T. Frederick, Juliana C. N. Kenski, Mara Parren, Marieke Brüggemann, Max F. Madu, Elisa A. Rozeman, Ji-Ying Song, Hugo M. Horlings, Christian U. Blank, Alexander C. J. van Akkooi, Keith T. Flaherty, Genevieve M. Boland, Daniel S. Peeper
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/654c30ddffb84e7c908534d36b55c498
Autor:
Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke, Lisanne P. Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi, John B. A. G. Haanen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpe
Externí odkaz:
https://doaj.org/article/7d1e6b458ad644d8942e1babbaf34492
Autor:
Julia Boshuizen, David W. Vredevoogd, Oscar Krijgsman, Maarten A. Ligtenberg, Stephanie Blankenstein, Beaunelle de Bruijn, Dennie T. Frederick, Juliana C. N. Kenski, Mara Parren, Marieke Brüggemann, Max F. Madu, Elisa A. Rozeman, Ji-Ying Song, Hugo M. Horlings, Christian U. Blank, Alexander C. J. van Akkooi, Keith T. Flaherty, Genevieve M. Boland, Daniel S. Peeper
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Dedifferentiation state has been associated with therapy resistance in melanoma. Here, the authors uncover a pre-existing NGFR-expressing, targetable subpopulation that is resistant to immunotherapy and other treatments in melanoma cells and preclini
Externí odkaz:
https://doaj.org/article/0aa2077077d243cb9f117c28a0c8e4f1
Autor:
Annegien Broeks, Michel W J M Wouters, Georgina V Long, Richard A Scolyer, Christian U Blank, Judith M Versluis, Karijn P M Suijkerbuijk, Petros Dimitriadis, Joyce Sanders, James S Wilmott, Alexander Maxwell Menzies, Yvonne M Schrage, Stephanie A Blankenstein, Robert Elens, Willeke A M Blokx, Winan van Houdt, Alexander C J van Akkooi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background A substantial proportion of patients with macroscopic stage III melanoma do not benefit sufficiently from adjuvant anti-PD-1 therapy, as they either recur despite therapy or would never have recurred. To better inform adjuvant treatment se
Externí odkaz:
https://doaj.org/article/e0b90991b4304091afe1ffd233fc064c
Autor:
Viola, Franke, Emma H A, Stahlie, Willem M C, Klop, Charlotte L, Zuur, Danique M S, Berger, Bernies, van der Hiel, Bart A, van de Wiel, Michel W J M, Wouters, Winan J, van Houdt, Alexander C J, van Akkooi
Publikováno v:
Melanoma Research. 33:66-70
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1, intralesionally administered in patients with stage IIIB/C-IVM1a unresectable melanoma. When surgery is not a treatment option in the head and neck region, T-VEC can be an e
Autor:
Eva A. Huis in ′t Veld, Thomas Boere, Charlotte L. Zuur, Michel W. Wouters, Alexander C. J. van Akkooi, John B. A. G. Haanen, Marianne B. Crijns, Myles J. Smith, Antien Mooyaart, Marlies Wakkee, Aniel Sewnaik, Dirk C. Strauss, Dirk J. Grunhagen, Cornelis Verhoef, Andrew J. Hayes, Winan J. van Houdt
Publikováno v:
Annals of Surgical Oncology.
Publikováno v:
Annals of Surgical Oncology. 30:1279-1281
Autor:
Richard J. B. Walker, Nicole J. Look Hong, Marc Moncrieff, Alexander C. J. van Akkooi, Evan Jost, Carolyn Nessim, Winan J. van Houdt, Emma H. A. Stahlie, Chanhee Seo, May Lynn Quan, J. Gregory McKinnon, Frances C. Wright, Michail N. Mavros
Publikováno v:
Annals of Surgical Oncology. 29:7010-7017
Autor:
Alexander C J, van Akkooi, Tina J, Hieken, Elizabeth M, Burton, Charlotte, Ariyan, Paolo A, Ascierto, Salvatore V M A, Asero, Christian U, Blank, Matthew S, Block, Genevieve M, Boland, Corrado, Caraco, Sydney, Chng, B Scott, Davidson, Joao Pedreira, Duprat Neto, Mark B, Faries, Jeffrey E, Gershenwald, Dirk J, Grunhagen, David E, Gyorki, Dale, Han, Andrew J, Hayes, Winan J, van Houdt, Giorgos C, Karakousis, Willem M C, Klop, Georgina V, Long, Michael C, Lowe, Alexander M, Menzies, Roger, Olofsson Bagge, Thomas E, Pennington, Piotr, Rutkowski, Robyn P M, Saw, Richard A, Scolyer, Kerwin F, Shannon, Vernon K, Sondak, Hussein, Tawbi, Alessandro A E, Testori, Mike T, Tetzlaff, John F, Thompson, Jonathan S, Zager, Charlotte L, Zuur, Jennifer A, Wargo, Andrew J, Spillane, Merrick I, Ross
Publikováno v:
Annals of Surgical Oncology, 29(6), 3694-3708. Springer New York
Exciting advances in melanoma systemic therapies have presented the opportunity for surgical oncologists and their multidisciplinary colleagues to test the neoadjuvant systemic treatment approach in high-risk, resectable metastatic melanomas. Here we
Autor:
Viola, Franke, Emma H A, Stahlie, Bernies, van der Hiel, Bart A, van de Wiel, Michel W J M, Wouters, Winan J, van Houdt, Alexander C J, van Akkooi
Publikováno v:
Journal of Immunotherapy. 45:263-266
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus type 1, which can be administered intralesionally in patients with stage IIIB/C-IVM1a (American Joint Committee of Cancer; AJCC 7th edition) unresectable melanoma. In the case of dis